33 Bamlanivimab Reduces COVID-19-Related Emergency Department Return Visits and Hospitalizations at a Rural US-Mexican Border Hospital
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Emergency Medicine"
DOI: 10.1016/j.annemergmed.2021.07.034
Abstract: Study Objective: To evaluate the effectiveness of bamlanivimab in reducing return emergency department (ED) visits in primarily Latinx/Hispanic patients diagnosed with mild or moderate coronavirus disease 2019 (COVID-19) during a hospital surge. Secondary aims were… read more here.
Keywords: return visits; bamlanivimab; group; hospital ... See more keywords
Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2081450
Abstract: Abstract Coronavirus Disease 2019 (COVID-19) is affecting millions of people globally. Several neutralizing monoclonal antibodies have been developed to limit the progression and complications of the disease. These treatments provide immediate and passive immunity. The… read more here.
Keywords: aberrant ventricular; ventricular conduction; fibrillation; bamlanivimab ... See more keywords
SARS‐CoV‐2 neutralizing antibodies for COVID‐19: Outcomes for bamlanivimab versus bamlanivimab‐etesevimab combination in a racially diverse cohort of patients with significant comorbidities
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13694
Abstract: Anti‐spike monoclonal antibodies (MAB) including bamlanivimab (BAM) and bamlanivimab/etesevimab (BAM/E) have shown reduced hospitalization rates for non‐severe coronavirus disease 2019 (COVID‐19) in clinical trials. Recent data have provided real‐world hospitalization rates for high‐risk patients treated… read more here.
Keywords: cov neutralizing; neutralizing antibodies; bamlanivimab; cohort ... See more keywords
Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15121472
Abstract: Little is known about cardiovascular safety profiles for monoclonal antibody products that received the FDA Emergency Use Authorization for COVID-19. In this study, data from the FDA Adverse Event Reporting System from the first quarter… read more here.
Keywords: safety; monoclonal antibody; antibody products; bamlanivimab ... See more keywords
Neutralizing Antibody Therapeutics for COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "Viruses"
DOI: 10.3390/v13040628
Abstract: The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. In this article, we review the role of SARS-CoV-2… read more here.
Keywords: bamlanivimab; neutralizing antibody; therapeutics covid; covid ... See more keywords
Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals
Sign Up to like & getrecommendations! Published in 2022 at "Western Journal of Emergency Medicine"
DOI: 10.5811/westjem.2021.10.52668
Abstract: Introduction To evaluate the effectiveness of bamlanivimab at reducing return emergency department (ED) visits in primarily Latinx/Hispanic patients with mild or moderate coronavirus disease 2019 (COVID-19). Secondary aims were to evaluate the prevention of subsequent… read more here.
Keywords: resource; group; covid; risk ... See more keywords